Seroatlas · Human Serome Atlas

CMA1

Chymase

Also known as: CMA1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P23946
Gene: CMA1
Ensembl: ENSG00000092009
Chromosome: 14
Canonical length: 247 aa
Protein class: Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
Subcellular location: Cytosol,Cytoplasmic bodies
Secretome location: Secreted to blood

OverviewNCBI Gene

This gene encodes a chymotryptic serine proteinase that belongs to the peptidase family S1. It is expressed in mast cells and is thought to function in the degradation of the extracellular matrix, the regulation of submucosal gland secretion, and the generation of vasoactive peptides. In the heart and blood vessels, this protein, rather than angiotensin converting enzyme, is largely responsible for converting angiotensin I to the vasoactive peptide angiotensin II. Alternative splicing results in multiple variants. [provided by RefSeq, Apr 2015]

Canonical amino-acid sequenceUniProt

247 residues, UniProt reviewed canonical sequence.

>P23946|CMA1
     1  MLLLPLPLLL FLLCSRAEAG EIIGGTECKP HSRPYMAYLE IVTSNGPSKF CGGFLIRRNF
    61  VLTAAHCAGR SITVTLGAHN ITEEEDTWQK LEVIKQFRHP KYNTSTLHHD IMLLKLKEKA
   121  SLTLAVGTLP FPSQFNFVPP GRMCRVAGWG RTGVLKPGSD TLQEVKLRLM DPQACSHFRD
   181  FDHNLQLCVG NPRKTKSAFK GDSGGPLLCA GVAQGIVSYG RSDAKPPAVF TRISHYRPWI
   241  NQILQAN

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CMA1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.28
Highest tissue expression: 17 nTPM

Expression across tissuesHPA

Tissue

breast: 17 nTPM
urinary bladder: 10 nTPM
esophagus: 9.6 nTPM
adipose tissue: 8.5 nTPM
colon: 8.2 nTPM
skin: 8.1 nTPM

Single-cell type

mast cells: 161 nCPM
smooth muscle cells: 5.2 nCPM
pdcs: 1.8 nCPM
enteric transient amplifying cells: 0.4 nCPM
esophageal apical cells: 0.4 nCPM
basal keratinocytes: 0.2 nCPM

Immune cell

T-reg: 0.2 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

medulla oblongata: 1.8 nTPM
midbrain: 1.4 nTPM
spinal cord: 1.4 nTPM
choroid plexus: 1.3 nTPM
cerebral cortex: 1.2 nTPM
hypothalamus: 1.2 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.88
gnomAD pLI: 0
gnomAD missense Z: -1.75
DepMap mean gene effect: 0.14
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CMA1 as an antibody target. Whether an autoantibody or antibody against CMA1 could matter depends on whether native CMA1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CMA1 is annotated as secreted, so native CMA1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label CMA1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...